Key facts
- Peca Labs’s last known valuation is $88.0M (Nov 2025).
- It has raised $27.1M across 7 recorded rounds; the latest was Seed Round ($2.7M) in Nov 2025.
- Notable investors include Innovation Works, Carnegie Mellon University, Allegheny Financial Group, BlueTree Allied Angels, Children's National — 11 tracked in total.
- Peca Labs has filed 9 Form Ds with the SEC since 2015, most recently Nov 2025 ($2.7M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Peca Labs
Funding rounds
7 roundsAbout Peca Labs
Developer of polymer-based cardiovascular implants designed to improve the treatment of cardiac defects. The company offers polymeric heart valves and vascular grafts with a valved shunt for hypoplastic left heart syndrome, enabling pediatric surgeons to reduce the need for repeated open-heart procedures in children over time.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2012
- Employees
- 30
- Website
- pecalabs.com/
- Ownership
- Privately Held (backing)
Peca Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peca Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peca Labs in its N-PORT filings yet. We sweep new filings monthly.